Biomerica, Inc. BMRA

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
33/100
Developing

Ranked against 159 peers in Medical Devices

About Biomerica, Inc.

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as … Full BMRA analysis →

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.68). Improving FCF margin signals compounding operational leverage.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.10). May indicate commodity-like product mix or distributor margin drag.
  • Weak Capital Return Profile Capital return quality is below peers (score 0.23). Low ROIC raises questions about M&A discipline and pipeline ROI.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
29
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where BMRA ranks in Medical Devices

Biomerica, Inc. ranks #125 of 160 scored companies in Medical Devices by moat score — the top 78%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

# Company Moat score Rating
121 Tenon Medical, Inc. TNON 34/100 Developing
122 Bone Biologics Corp BBLG 34/100 Developing
123 BONE BIOLOGICS CORP C/WTS (TO P BBLGW 33/100 Developing
124 NeuroMetrix, Inc. NURO 33/100 Developing
125 Biomerica, Inc. BMRA 33/100 Developing
126 IceCure Medical Ltd. ICCM 32/100 Developing
127 Vivos Therapeutics, Inc. VVOS 31/100 Developing
128 Modular Medical, Inc. MODD 31/100 Developing
129 Elutia, Inc. ELUT 29/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How BMRA scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 29 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 30 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 49 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 34 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 22 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 20 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding BMRA's moat

What is Biomerica, Inc.'s moat score?

Biomerica, Inc. (BMRA) scores 33 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #125 of 160 scored companies in Medical Devices, the top 78%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is FCF Quality & Cash Conversion (49/100) and its weakest is Growth Durability (20/100).

How does Biomerica, Inc. compare with other Medical Devices companies?

Biomerica, Inc. ranks #125 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are NeuroMetrix, Inc. (NURO) at 33 just above it and IceCure Medical Ltd. (ICCM) at 32 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is Biomerica, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Biomerica, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and BMRA scores: Pricing Power & Consumable Moat (29), R&D Pipeline & Capital Returns (30), FCF Quality & Cash Conversion (49), Commercial Execution (34), Capital Structure & Resilience (22), Growth Durability (20). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000